Daxor announces expansion of its BVA platform into three new facilities

Daxor (DXR) Corporation announces the expansion of its Blood Volume Analysis, BVA, platform into three new facilities. This milestone demonstrates the accelerating market adoption of BVA’s pivotal role in precision fluid management, leading to improved patient outcomes and reduced healthcare costs. This growth is propelled by Daxor’s dual-solution strategy: the initial onboarding of our new on-site BVA analyzer at select locations and CLIA-certified ezBVA Lab Service. The company anticipates continued strong sales momentum as clinicians embrace this essential diagnostic tool.